Show simple item record

dc.contributor.authorMcilwain, Meghan E
dc.contributor.authorHarrison, Jeff
dc.contributor.authorWheeler, Amanda J
dc.contributor.authorRussell, Bruce R
dc.date.accessioned2017-05-03T15:56:24Z
dc.date.available2017-05-03T15:56:24Z
dc.date.issued2011
dc.date.modified2011-10-12T06:47:44Z
dc.identifier.issn1176-6328
dc.identifier.doi10.2147/NDT.S12769
dc.identifier.urihttp://hdl.handle.net/10072/39713
dc.description.abstractSchizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are generally less amenable to treatment. Because of the consequences of inadequate symptom control, effective treatment strategies are required for people with treatment-resistant schizophrenia. Clozapine has been shown to be more effective than other antipsychotics in treatment-resistant populations in several studies; however, the occurrence of adverse effects, some of which are potentially life-threatening, are important limitations. In addition to those who are intolerant to clozapine, only 30% to 50% experience clinically significant symptom improvement. This review describes the recent evidence for treatment strategies for people not responding to nonclozapine antipsychotic agents and people not responding or only partially responding to clozapine.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent224293 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherDove Medical Press Ltd.
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom135
dc.relation.ispartofpageto149
dc.relation.ispartofjournalNeuropsychiatric Disease and Treatment
dc.relation.ispartofvolume7
dc.rights.retentionY
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchNeurosciences
dc.subject.fieldofresearchClinical pharmacology and therapeutics
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3209
dc.subject.fieldofresearchcode321402
dc.titlePharmacotherapy for treatment-resistant schizophrenia
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.rights.copyright© 2011 Mcilwain et al, publisher and licencee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Please refer to the journal's website for access to the definitive, published version.
gro.date.issued2011
gro.hasfulltextFull Text
gro.griffith.authorWheeler, Amanda


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record